HOME >> BIOLOGY >> NEWS
Treatment extends survival in mouse model of spinal muscular atrophy

(TSA) that is in a class of drugs called histone deacetylase (HDAC) inhibitors. These drugs increase the activity of certain genes in the body.

Previous studies have shown that HDAC inhibitors can increase the amount of SMN2 expression in cultured cells and that treating pregnant mice with an HDAC inhibitor can increase the survival of their babies with SMA. Preliminary clinical trials are now underway to test several HDAC inhibitors in children who have SMA. However, the drugs in those clinical trials are weak HDAC inhibitors with other biological effects that may limit their usefulness for treating this disease. More importantly, none of the previous studies has demonstrated that HDAC inhibitors can extend survival when delivered after symptoms appeared. In the new study, the investigators tested TSA, which is a potent HDAC inhibitor, in cells from SMA patients and in a mouse model of SMA. They found that the drug increased the amount of SMN2 gene activity in both the cultured cells and the mouse model.

Next, the researchers gave daily injections of TSA to the SMA mice, starting when the mice were 5 days old. By that time, the mice showed clear symptoms of disease: they were significantly underweight and they had a markedly impaired righting reflex, or ability to get on their feet after being placed on their backs. The treated mice lived 19 percent longer, on average, than mice that did not receive TSA. About three-fourths of the treated mice had improved survival compared to control mice. The other fourth showed no improvement.

The treated mice had less weight loss and better righting reflexes, walking ability, and forelimb grip strength than mice that did not receive TSA. Examination showed that the TSA-treated mice also had larger neurons in the spinal cord, thicker muscle fibers, and more muscle mass than untreated mice. "This is a proof-of-concept experiment," says Dr. Sumner. "It clearly demonstrates that this treatment c
'"/>

Contact: Natalie Frazin
301-496-5924
NIH/National Institute of Neurological Disorders and Stroke
22-Feb-2007


Page: 1 2 3

Related biology news :

1. Treatment-induced growth factor causes cancer progression
2. Water Treatment and Reuse -- II
3. Treatments for urinary infections leave bacteria bald, happy and vulnerable
4. Treatment disconnect in kidney cancer: Rising mortality despite more small tumors, more surgery
5. Evolving Issues in the Prevention and Treatment of Influenza: A media forum
6. NHLBI media availability: Treatment shows long-term benefits for cystic fibrosis patients
7. Treatments have same target, different responses for lung cancer patients with genetic mutation
8. Back to the future: Mastodon extends the time limit on DNA sequencing
9. Wiley extends publishing partnership with the American Institute of Chemical Engineers
10. Nexavar significantly extends overall survival by 44 percent in liver cancer patients
11. Vitamin extends life in yeast, Dartmouth Medical School researchers find

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/12/2020)... SOUTHFIELD, Mich. (PRWEB) , ... August 11, 2020 ... ... Janssen R&D subsidiary based in Princeton, NJ, have entered into license agreements with ... discovery and development. Both Roche and J&J have annual Research and Development ...
(Date:8/7/2020)... SAN FRANCISCO (PRWEB) , ... August 06, 2020 ... ... the life sciences industry, is pleased to announce that Eric Chen and Jessica ... Vice President of Product Management & Strategy, respectively. , Eric Chen heads development ...
(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... Editas Medicine, Inc. (Nasdaq: ... advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ... strategic partnership whereby Catalent will provide support for the development, manufacturing, and clinical ...
(Date:7/18/2020)... ... 16, 2020 , ... After research model surgery and catheter implantation, the long ... only the beginning of a successful study, while protecting and accessing the catheter or ... Head of Surgery from Envigo in a live webinar on ...
(Date:7/10/2020)... ... July 09, 2020 , ... PathSensors Inc., ... has expanded the company’s exclusive license to include clinical applications for CANARY™ ... market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast and highly ...
(Date:7/1/2020)... ... 29, 2020 , ... MedShift , a leading medical ... many obstacles created as a result of COVID-19. As a provider at the ... practices and medical manufacturers by expanding access to device offerings, technology services, and ...
Breaking Biology Technology:
Cached News: